Gates Foundation gives $220 mln for TB research

Microsoft billionaire Bill Gates and his wife are to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis, a company statement said Thursday.

Microsoft billionaire Bill Gates and his wife are to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis, a company statement said Thursday.

The Bill and Melinda Gates Foundation is donating the money to Aeras which from its bases in the United States and South Africa has developed six possible TB vaccines that are being tested across Africa, Asia, Europe and America.

"This infusion of funding must be seen as a global call to action in response to one of the world's deadliest diseases," said Jim Connolly, Aeras's president and chief executive, expressing gratitude for the massive grant.

"It will allow Aeras to expand upon existing partnerships in Europe, Africa, China, and around the world."

A total of 8.8 million people globally fell ill with the contagious in 2010 and around 1.4 million died, according to the (WHO).

Trevor Mundel, president of the global health program at the , said the development of successful vaccines "would be the single greatest advance in the global fight against TB."

Once known as "consumption" for the slow wasting away of the people who died of it, one out of every three people is thought to be infected by the airborne TB organism, though only a fraction go on to develop the disease.

The WHO estimates the global of TB is $12 billion a year, with India and China together accounting for more than half that cost.

add to favorites email to friend print save as pdf

Related Stories

Gates Foundation goes after TB

Sep 20, 2007

The Bill & Melinda Gates Foundation, based in Seattle, has announced $280 million in grants to fight a growing tuberculosis problem.

TB vaccine enters new clinical trials

Apr 23, 2009

(PhysOrg.com) -- The world’s leading candidate for a tuberculosis vaccine, developed at the University of Oxford, is to enter Phase IIb proof-of-concept clinical trials, making it the first TB candidate ...

New TB booster shows promise

Mar 16, 2010

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

Vaccine targeting latent TB enters clinical testing

Dec 01, 2011

Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease. The ...

Groundbreaking, lifesaving TB vaccine a step closer

Oct 08, 2008

Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development ...

Recommended for you

Nigeria confirms two new Ebola cases (Update)

1 hour ago

Two new cases of Ebola have emerged in Nigeria and, in an alarming development, they are outside the group of caregivers who treated an airline passenger who arrived with Ebola and died, Health Minister Onyebuchi ...

Senegal closes border as UN warns on Ebola flare-up

6 hours ago

Senegal has become the latest country to seal its border with a west African neighbour to ward off the deadly Ebola virus, as the new UN pointman on the epidemic said preparations must be made for a possible flare-up of the ...

Climate change could see dengue fever come to Europe

6 hours ago

Dengue fever could make headway in popular European holiday destinations if climate change continues on its predicted trajectory, according to research published in open access journal BMC Public Health.

American Ebola doc: 'I am thrilled to be alive'

14 hours ago

Calling it a "miraculous day," an American doctor infected with Ebola left his isolation unit and warmly hugged his doctors and nurses on Thursday, showing the world that he poses no public health threat ...

User comments